Opinion
Video
Author(s):
The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.
Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT
Revisit the OncLive On Air Episodes From February 2024
FDA Grants Fast Track Designation to ICT01 Plus Azacitidine/Venetoclax in Treatment-Naive AML
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes
Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma
Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma
Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma